Parag Saxena - 18 Dec 2025 Form 4 Insider Report for REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)

Reporting relationship: Director
Issuer ticker: RVPH
Reported as of: 18 Dec 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 Dec 2025, 16:17:26 UTC
Prior SEC filing: 12 Dec 2024
Source filing: View source filing
Reporting owner signature: /s/ Parag Saxena

Key filing fact

Parag Saxena filed Form 4 for REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) on 19 Dec 2025.

Key facts

This page summarizes Parag Saxena's Form 4 filing for REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 19 Dec 2025, 16:17.

Change

Previous filing in this sequence was filed on 12 Dec 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001015823 Primary reporting owner

SAXENA PARAG

Relationship: Director
Address: C/O VEDANTA MANAGEMENT LP, 250 WEST 55TH STREET, SUITE 13D, NEW YORK
Signature: /s/ Parag Saxena
Signature date: 19 Dec 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RVPH transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +8,200
Change %
Price: $0.000000
Shares after: 8,200
Date: 18 Dec 2025
Ownership: Direct
Underlying class: Common Stock, par value $0.0001 per share
Underlying amount: 8,200
Exercise price: $0.5848
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option award (the "Option") was made in accordance with the terms of the 2020 Equity Incentive Plan (the "2020 Plan") of Reviva Pharmaceuticals Holdings, Inc. (the "Company"). The Option will vest at the rate of one hundred percent (100%) of the shares of common stock, par value $0.0001 per share ("Common Stock"), subject thereto upon the one year anniversary of the date of grant, provided that the reporting person remains a director of the Company through such vesting date. The exercise price is based on the closing price of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan.